Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...

Despite reporting decent earnings for the July-September quarter, brokerages continue to maintain their neutral stance over ...

Dr. Reddy’s Laboratories consolidated net profit declined 9.5% for the September quarter to ₹1,341.9 crore compared to ₹1,482.2 crore in the year earlier period even as the generic drugmaker reported ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended September 30 ...

The Board of Directors of Dr. Reddys Laboratories Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 ...

HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in consolidated net profit for the Sept ...

Pharma major Dr Reddy’s Laboratories is expected to post a decline in net profit in the second quarter of current fiscal year ...

With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

The company reported a 9.5% fall in its consolidated net profit after tax to 13.42 billion rupees ($159.6 million) for the quarter ended Sept. 30, missing analysts' estimate of 14.01 billion rupees, ...